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Background and aims: The recently identiﬁedadipokineomentin-1 is inverselyassociatedwithbody fatness,
metabolic syndrome and cardiovascular disease (CVD) in cross-sectional analyses. However, prospective data
on the association between plasma omentin-1 levels and future risk of CVD are lacking. The aim of the study
was to investigate the relationship between omentin-1 and incident myocardial infarction (MI) and stroke.
Methods: We conducted a case-cohort study nested within the European Prospective Investigation into
Cancer and Nutrition (EPIC)-Potsdam cohort comprising a subsample of 2084 participants, including 50
CVD cases and 350 external incident CVD cases (mean follow-up of 8.2 ± 1.6 years). Prentice modiﬁed
Cox regression adjusted for established CVD risk factors was used to estimate associations between
omentin-1 and risk of MI and stroke, interactions were tested with cross-product terms.
Results: After multivariable adjustment, omentin-1 was not signiﬁcantly associated with risk of MI (HR
per doubling omentin-1:1.17; 95%-CI:0.79e1.72; p ¼ 0.43), but with higher risk of stroke (HR per
doubling omentin-1:2.22; 95%-CI:1.52e3.22; p < 0.0001). In subgroup analyses, associations between
omentin-1 and stroke risk were generally stronger in lower versus higher CVD risk groups. For example,
risk of stroke was stronger in participants without metabolic syndrome (HR per doubling omentin-
1:2.58; 95%-CI:1.64e4.07; p < 0.0001) compared to those with metabolic syndrome (HR per doubling
omentin-1:1.21; 95%-CI:0.59e2.50; p ¼ 0.60) (p for interaction ¼ 0.05). Similar interactions were
observed when participants were classiﬁed in low or high risk groups according to waist circumference,
triglyceride, hsCRP or adiponectin levels.
Conclusions: Omentin-1 concentrations may be related to increased stroke risk. This association is
stronger in metabolically healthy individuals.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Epidemiology, German Insti-
hur-Scheunert-Allee 114-116,
).
r Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Flow diagram. Flow diagram for the exclusion criteria indicating the number of
subjects excluded and those remaining for the main analysis.
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Omentin-1, also referred to intelectin-1 or intestinal lactoferrin
receptor ITLN1, was discovered as novel fat depot-speciﬁc secretory
protein from a human omental fat cDNA library [1]. This adipokine
is mainly expressed in visceral adipose stromal vascular cells, rather
than in subcutaneous adipose, but also in lung, heart, placenta, and
ovary tissue [1,2]. Omentin occurs in two highly homologous iso-
forms of omentin-1 and omentin-2, but omentin-1 has been shown
to be the major circulating isoform in human plasma [3,4]. Recent
studies have observed that omentin-1 is inversely related to body
mass index and waist circumference [3]. Positive associations with
adiponectin and high density lipoprotein (HDL) cholesterol were
also reported [3]. Based on these reported relationships, a possible
protective role of omentin-1 in the pathogenesis of atherosclerosis
and risk of CVD has been hypothesized.
However, to date, mainly cross-sectional studies investigated
the relationship between omentin-1 and cardiovascular endpoints,
often performed in patients with preexisting diseases [4,5]. For
example Lui et al. found an inverse association between omentin-1
levels and carotid artery intima-media thickness in patients with
metabolic syndrome (MetS) [4]. Greulich et al. suggested that
decreased omentin-1 levels were associated with cardiovascular
dysfunction in patients with type 2 diabetes [5]. Moreover, patients
with coronary artery disease (CAD) had lower omentin-1 levels
[6e10].
Prospective studies investigating the relationship between
omentin-1 and CVD incidence in apparently healthy participants
are still missing. Therefore, our study aimed to investigate the
longitudinal association between circulating omentin-1 concen-
trations and risk of myocardial infarction (MI) and stroke in
apparently healthy men and women of the EPIC-Potsdam study.
2. Materials and methods
2.1. Study population
The European Prospective Investigation into Cancer and Nutri-
tion (EPIC)-Potsdam study consists of 16 644 women and 10 904
men recruited between 1994 and 1998 from the general population
in Potsdam and surroundings [11].
About every 2 years, information on incident diseases was
collected. To identify potential CVD cases several sources were
used: self-report, death certiﬁcate or linkage with hospital infor-
mation system. To increase sensitivity, the questionnaire included
additional questions about typical stroke symptoms [12e14]. All
identiﬁed potential CVD events were ascertained by study physi-
cians, in cooperation with the patients’ attending physicians and
hospitals, who provided a detailed medical veriﬁcation of self-
reports and death certiﬁcates by clinical records according to the
World Health OrganizationMonitoring of Trends and Determinants
in Cardiovascular Disease criteria [15]. According to the Interna-
tional Statistical Classiﬁcation of Diseases, 10th Revision (ICD-10),
cases were classiﬁed as incident MI (ICD-10 I21), ischemic stroke
(IS) (ICD-10 I63.0 to I63.9), hemorrhagic stroke (ICD-10 I60.0 to
I61.9) or undetermined stroke (ICD-10 I64.0-I64.9) [16]. All veriﬁed
incident cases of MI and stroke up to December 2008 were
included.
A case-cohort design was applied, using all incident CVD cases
and a subcohort of 2500 individuals randomly drawn from all
participants of the EPIC-Potsdam study, who provided blood
(n ¼ 26 444). This design enables efﬁcient analyses according to
time and costs, whereas the results are expected to be generalizable
without the need to measure biomarker levels in the entire cohort
[17]. After exclusion of individuals with prevalent stroke or MI(n ¼ 85), missing follow-up data (n ¼ 53), inappropriate blood
sample (n ¼ 213), missing covariates (n ¼ 107) and unreliable
omentin-1 measurements (n ¼ 86), the ﬁnal study population
consisted of a subcohort of 2084 participants, including 50 CVD
cases, and 350 veriﬁed external incident CVD cases that occurred
during 8.2 ± 1.6 years of follow-up (Fig. 1). Participants gave their
written informed consent, and study procedures were approved by
the Ethics Committee of the Medical Association of the State of
Brandenburg.
2.2. Assessment of risk factors and covariates
Lifestyle characteristics, including physical exercise, education
and smoking history, were documented at baseline by trained in-
terviewers during a computer-assisted interview [11]. History of
hypertensionwas deﬁned as systolic blood pressure140mmHg or
diastolic blood pressure 90 mmHg, self-reports or use of antihy-
pertensivemedication. The history of diabetes was evaluated by the
study physician using information on self-reported diagnosis,
medication records and dieting behavior. Dietary habits including
alcohol consumption were assessed by a validated food frequency
questionnaire [11].
2.3. Blood collection and laboratory analysis
All markers were measured in citrate plasma. Biomarkers other
than omentin-1 were determined at the Department of Internal
Medicine, University of Tübingen. Plasma levels of high-density
lipoprotein (HDL) cholesterol, total cholesterol, triglycerides,
high-sensitivity C-reactive protein (hsCRP) were measured with
the automatic ADVIA 1650 analyzer (Siemens Medical Solutions,
Erlangen, Germany) in 2007. Adiponectin was measured with an
enzyme-linked immunosorbent assay from Linco Research, St
Charles, Missouri in 2008.
Plasma omentin-1 concentrations were measured with a sand-
wich ELISA by Biovendor (Brno, Czech Republic) at the Institute for
Clinical Chemistry and Pathobiochemistry, OvGU, Magdeburg,
Germany (intra-assay coefﬁcients of variation between 3.2% and
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with a limit of detection of 0.5 ng/ml, according to the
manufacturer.
2.4. Statistical analysis
A multivariable adjusted analysis of covariance was performed
to investigate associations between omentin-1 concentrations and
several cardiovascular risk factors across quartiles of omentin-1
concentrations within the subcohort.
Prentice modiﬁed Cox proportional-hazards regression was
used to estimate the associations between omentin-1 and risk of
MI, stroke or its subtypes. Age was used as underlying time axis
with ‘‘entry time’’ deﬁned as age at baseline and ‘‘exit time’’ as age
at diagnosis of MI or stroke or censoring. Hazard ratios (HR) were
adjusted for sex and age (Model 1), waist circumference, smoking,
physical activity, education, alcohol consumption, prevalent hy-
pertension, prevalent diabetes, HDL-cholesterol, total cholesterol,
triglycerides and hsCRP (Model 2), and adiponectin (Model 3).
Alcohol consumption, triglycerides, hsCRP and adiponectin were
natural log transformed. For linear relationship, on a continuous
scale, omentin-1 was base 2 logarithm transformed, enabling the
interpretation of increasing CVD risk per doubling of omentin-1
values. The risk of MI and stroke was furthermore evaluated ac-
cording to quartiles of omentin-1 using the ﬁrst quartile as
reference.
Competing risk analysis, as described by Lunn and McNeil [18],
was applied to test whether the associations of omentin-1 differed
between MI and stroke, and additionally between ischemic and
hemorrhagic stroke.
Possible nonlinear relationships were examined with restricted
cubic splines (RCS) with ﬁve knots at the 5th, 35th, 50th (reference),
65th and 95th percentile of omentin-1 in the fully adjusted model.
The Wald chi-square test was used to select the best-ﬁt model.
Effect modiﬁcations between selected CVD risk factors
(dichotomous) and omentin-1 (continuous) in relation to MI and
stroke risks were tested with cross-product terms in model 3.
Stratiﬁed analyses were performed according to established cutoff
points: waist circumference (women </ 88 cm; men </ 102 cm)
[19], HDL-cholesterol (women </ 1.29 mmol/l; men </
1.04 mmol/l) [19], triglycerides (</ 1.69 mmol/l) [19], hsCRP (</
1.0 mg/l) [20]. For adiponectin the sex-speciﬁc median from the
subcohort was used (women </ 9.14 mg/ml; men </ 5.98 mg/ml).
Metabolic syndrome was deﬁned using the American Heart Asso-
ciation/National Heart, Lung and Blood Institute criteria [19].
The proportional hazard assumption was tested by a
Kolmogorov-type supremum test. No violation was found. A p-
value <0.05 was considered to be statistically signiﬁcant, for in-
teractions p-value was increased to 0.10. Sensitivity analyses were
performed after exclusion of ﬁrst 2 years of follow-up, to account
for the latency period between pathology and clinical diagnosis.
Additionally Cox proportional-hazards regression analyses were
applied to estimate the associations between omentin-1 and risk of
MI and stroke with further adjustment of antidiabetic medication,
antihypertensive medication and lipid-lowering medication in
model 2 and model 3. All statistical analyses were performed using
SAS software, version 9.4 (SAS institute, Cary, N.C., USA).
3. Results
Participants with incident MI or stroke were older and more
likely to be male compared to persons without CVD events(Supplemental Table 1). After adjustment for age and sex, persons
with CVD events at baseline were also more likely to be smokers
and to have a history of diabetes and hypertension compared to
those without CVD events (Supplemental Table 1).
Within the subcohort, a cross-sectional multivariable adjusted
analysis of covariance across quartiles of omentin-1 showed sig-
niﬁcant positive associations with age, physical activity, and history
of diabetes, HDL-cholesterol, adiponectin, and alcohol consump-
tion, signiﬁcant inverse associations were observed with waist
circumference (Table 1).
Participants in the highest quartile of omentin-1 levels had a
signiﬁcantly increased risk of stroke (Model 3, HR: 2.29; 95%-con-
ﬁdence interval (CI) 1.38e3.79; p linear trend ¼ 0.0003) compared
to participants in the lowest quartile (Table 2). Positive associations
were also observedwhen omentin-1wasmodelled on a continuous
scale (Model 3 per doubling of omentin-1, HR: 2.22; 95%-CI:
1.52e3.22; p < 0.0001). Separated analyses showed increased risk
of both ischemic and hemorrhagic stroke in the highest versus the
lowest quartile of omentin-1 (Table 2). However, no relationship
was observed between omentin-1 and risk of MI (Table 2 and
Fig. 2).
In a competing risk analysis, a signiﬁcant difference in the as-
sociation between omentin-1 and MI versus omentin-1 and stroke
was detected (p ¼ 0.02). However, no difference was observed in
the associations between omentin-1 and ischemic stroke versus
omentin-1 and hemorrhagic stroke (p ¼ 0.43).
There was no evidence of departure from linearity for the
relation between omentin-1 and stroke risk (p for non-
linearity ¼ 0.82). We found no signiﬁcant non-linear associations
between omentin-1 and risk of MI (Fig. 2).
Stratiﬁed analyses according to CVD risk subgroups showed an
association between omentin-1 and increased stroke risk in
particular in metabolically healthy individuals. As presented in
Table 3, in participants with high adiponectin levels higher
omentin-1 levels were related to a higher risk of stroke (HR per
doubling omentin-1: 3.52; 95%-CI: 2.08e5.94; p < 0.0001), and
omentin-1 was not associated with stroke risk in participants with
low adiponectin levels (HR per doubling omentin-1: 1.14, 95%-CI:
0.65e2.01, p ¼ 0.65) (p for interaction ¼ 0.02). Furthermore, risk of
stroke was stronger in participants without MetS (HR per doubling
omentin-1: 2.58; 95%-CI: 1.64e4.07; p< 0.0001) compared to those
with MetS (HR per doubling omentin-1: 1.21; 95%-CI: 0.59e2.50;
p ¼ 0.60) (p for interaction ¼ 0.05). Similar interactions were
observed when participants were classiﬁed in low or high risk
groups according to waist circumference (p for interaction ¼ 0.03),
triglyceride (p for interaction ¼ 0.09) or hsCRP (p for
interaction¼ 0.08). According toMI risk, stratiﬁed analyses showed
a decreasedMI risk in participants withMetS and a strongerMI risk
in individuals without MetS (p for interaction ¼ 0.02), though both
associations were not statistically signiﬁcant (Supplemental
Table 2).
After exclusion of cases that occurred during the ﬁrst 2 years of
follow-up, the hazard ratios of stroke andMI according to omentin-
1 concentrations remained unaltered (data not shown). Further, we
observed no changes in results with additionally adjustment of
antidiabetic medication, antihypertensive medication and lipid-
lowering medication in the main multivariable analysis (Model 2
and Model 3, data not shown).4. Discussion
In this prospective analysis, we observed that higher levels of
Table 1
Characteristics of the subcohort according to omentin-1 quartiles.
Characteristics Quartiles of omentin-1 in the subcohorta p linear trendc p linear trendd
Q1 Q2 Q3 Q4
n 519 525 519 521
Omentin-1 [ng/ml]b 286.5 (250.6e308.6) 363.1 (343.4e380.3) 439.6 (420.0e462.8) 569.6 (517.4e642.6)
Men [%]c 41.2 36.6 37.7 33.5 0.02 0.1
Age [years]c 47.4 (46.6e48.1) 48.8 (48.1e49.5) 51.9 (51.1e52.6) 53.9 (53.2e54.6) <0.0001 <0.0001
Waist circumference [cm] 89.8 (88.8e90.7) 87.4 (86.5e88.3) 86.6 (85.7e87.5) 85.1 (84.2e86.0) <0.0001 <0.0001
Physical activity, [h/week] 0.88 (0.73e1.03) 0.91 (0.76e1.05) 0.98 (0.83e1.13) 1.26 (1.11e1.41) 0.0005 0.01
Smoking [%] 0.3 0.5
Non-smoker 43.1 43.3 40.7 46.9
Ex-smoker < 5 years 26.1 27.3 28.4 24.8
Ex-smoker  5 years 7.4 6.4 8.7 8.9
Smoker < 20 cigarettes/day 16.0 14.9 17.2 12.6
Smoker  20 cigarettes/day 7.3 8.1 4.9 6.8
Education [%] 0.7 0.4
Unskilled or skilled 35.4 35.0 35.2 35.4
Technical College 22.4 23.5 23.5 21.3
University degree 42.2 41.5 41.2 43.3
Prevalent diabetes [%] 3.7 3.8 4.6 5.9 0.07 0.0004
Antidiabetic medication [%] 1.6 1.6 3.1 3.2 0.03 0.0004
Prevalent hypertension [%] 50.7 48.7 47.4 49.6 0.6 0.06
Antihypertensive medication [%] 19.4 16.0 16.6 19.0 0.9 0.07
Lipid-lowering medication [%] 4.7 4.4 3.6 4.0 0.5 0.5
Total cholesterol [mmol/l] 5.24 (5.15e5.33) 5.26 (5.17e5.36) 5.26 (5.17e5.35) 5.37 (5.27e5.46) 0.08 0.4
HDL-cholesterol [mmol/l] 1.36 (1.32e1.39) 1.39 (1.36e1.42) 1.41 (1.38e1.44) 1.53 (1.50e1.56) <0.0001 0.03
Triglyceride [mmol/l] 1.64 (1.55e1.73) 1.53 (1.44e1.62) 1.66 (1.57e1.75) 1.47 (1.37e1.56) 0.0003 0.7
hsCRP [mg/l] 2.57 (2.26e2.89) 1.67 (1.37e1.97) 1.89 (1.59e2.20) 1.64 (1.33e1.95) <0.0001 0.06
Adiponectin [mg/ml] 6.99 (6.67e7.32) 7.78 (7.46e8.10) 8.23 (7.90e8.55) 9.30 (8.97e9.63) <0.0001 <0.0001
Alcohol [g/d] 14.6 (12.9e16.3) 16.5 (14.8e18.2) 16.6 (14.9e18.2) 19.4 (17.7e21.1) <0.0001 0.0004
a All variables were adjusted for sex and age, expressed as adjusted percentage or mean and 95%-CI.
b Unadjusted variable, expressed as median and interquartile range.
c Adjusted for sex, age; according to examined variable.
d Mutually adjusted for sex, age, waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol,
total cholesterol, triglycerides, hsCRP and adiponectin according to examined variable.
Table 2
Hazard ratios of MI and stroke according to quartiles and per doubling of omentin-1 levels.
Quartiles of omentin-1 levels p for trend Per doubling of omentin-1
Q1 Q2 Q3 Q4 p-value
Omentin-1 [ng/ml]a 286.5 (250.6e307.4) 364.2 (344.0e380.5) 439.6 (420.0e462.2) 571.9 (519.5e642.6)
Subcohort participants (n) 519 525 519 521
Follow-up time [years] 4245.8 4288.9 4304.1 4234.2
MI (n ¼ 2267)
Cases (n) 43 45 54 60
Sex and age adjusted Reference 0.99 (0.63e1.54) 0.91 (0.60e1.39) 0.95 (0.62e1.45) 0.80 0.96 (0.68e1.35) 0.79
Model 2b Reference 0.90 (0.56e1.44) 0.97 (0.62e1.51) 1.16 (0.73e1.83) 0.42 1.19 (0.81e1.75) 0.37
Model 3c Reference 0.89 (0.56e1.42) 0.96 (0.61e1.50) 1.13 (0.71e1.79) 0.48 1.17 (0.79e1.72) 0.43
Stroke (n ¼ 2251)
Cases (n) 24 34 55 85
Sex and age adjusted Reference 1.29 (0.75e2.23) 1.73 (1.05e2.84) 2.39 (1.50e3.82) <0.0001 2.12 (1.54e2.92) <0.0001
Model 2b Reference 1.26 (0.72e2.20) 1.63 (0.97e2.73) 2.42 (1.47e3.98) 0.0001 2.31 (1.59e3.35) <0.0001
Model 3c Reference 1.24 (0.71e2.16) 1.58 (0.94e2.66) 2.29 (1.38e3.79) 0.0003 2.22 (1.52e3.22) <0.0001
Ischemic stroke (n ¼ 2218)
Cases (n) 19 29 45 68
Sex and age adjusted Reference 1.37 (0.75e2.51) 1.73 (1.00e3.02) 2.31 (1.37e3.90) 0.0006 1.96 (1.38e2.79) 0.0002
Model 2b Reference 1.34 (0.72e2.47) 1.59 (0.89e2.85) 2.34 (1.34e4.10) 0.001 2.13 (1.41e3.20) 0.0003
Model 3c Reference 1.32 (0.71e2.43) 1.54 (0.86e2.76) 2.20 (1.25e3.86) 0.003 2.02 (1.34e3.05) 0.0008
Hemorrhagic stroke (n ¼ 2114)
Cases (n) 4 5 10 15
Sex and age adjusted Reference 1.23 (0.33e4.63) 2.19 (0.70e6.90) 3.18 (1.06e9.55) 0.009 2.62 (1.43e4.79) 0.002
Model 2b Reference 1.32 (0.35e4.97) 2.28 (0.74e7.05) 3.46 (1.11e10.8) 0.01 2.85 (1.43e5.68) 0.003
Model 3c Reference 1.30 (0.35e4.91) 2.28 (0.74e7.04) 3.37 (1.08e10.6) 0.01 2.80 (1.39e5.62) 0.004
Hazard ratios and 95%-CI were derived from Cox proportional hazard regression.
a Quartiles are based on the distribution of omentin-1 within the subcohort expressed as median and interquartile range.
b Additionally adjusted for waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total
cholesterol, triglycerides and hsCRP.
c Additionally adjusted for adiponectin levels.
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Table 3
Multivariable adjusted hazard ratios for stroke per doubling of omentin-1 for subgroups
Group Cases Subcohorta
Sex
Men 114 754
Women 84 1299
Waist circumference [cm]
< 102 men, < 88 women 134 1569
 102 men,  88 women 64 484
Metabolic syndromed
No 128 1649
Yes 70 402
HDL-cholesterol [mmol/l]
< 1.04 men, < 1.29 women 55 490
 1.04 men,  1.29 women 143 1563
Triglycerides [mmol/l]
< 1.69 123 1480
 1.69 75 573
Adiponectin [mg/ml]
< 5.98 men, < 9.14 women 91 1031
 5.98 men,  9.14 women 107 1022
hsCRP [mg/l]
< 1.0 90 1165
 1.0 108 888
a Subcohort without internal cases.
b p-values for interaction were calculated using dichotomous variables and log-transf
c Adjusted for age, sex, waist circumference, physical activity, education, smoking,
cholesterol, triglycerides, hsCRP, adiponectin.
d n ¼ 2249 due to MetS missing values.
Fig. 2. Hazard ratio curves. (A) Hazard ratio curves for the association between
omentin-1 levels and the risk of stroke. (B) Hazard ratio curves for the association
between omentin-1 levels and the risk of MI. The solid lines indicate hazard ratios of
stroke or MI as obtained by restricted cubic spline Cox regression with knots placed at
ﬁxed values (5th, 35th, 65th and 95th percentile of the distribution of omentin-1 in the
entire case-cohort). The reference was set at 50th percentile. Dashed lines indicate
95%-CI. Hazard ratios and 95%-CI bands are adjusted for age, sex, waist circumference,
physical activity, education, smoking, alcohol consumption, prevalent hypertension
and diabetes, HDL-cholesterol, total cholesterol, triglycerides, hsCRP, adiponectin. P for
nonlinearity was computed by Wald chi-square test.
J. Menzel et al. / Atherosclerosis 251 (2016) 415e421 419omentin-1 were signiﬁcantly associated with a higher risk of stroke
in metabolically healthy participants with normal waist circum-
ference, low levels of triglyceride and hsCRP, high adiponectin
levels and no MetS. On the contrary, omentin-1 was not signiﬁ-
cantly related to risk of MI.
To our knowledge, this is the ﬁrst prospective study investi-
gating potential associations between omentin-1 and risk of stroke
and MI in apparently healthy middle aged men and women. So far,
only two small prospective studies investigated the association
between omentin-1 and cardiovascular endpoints in patients with
heart disease, providing conﬂicting ﬁndings [21,22]. In linewith our
study, Saely et al. reported an association between higher plasma
omentin-1 levels and higher risk of cardiovascular events in 295
CAD patients [22,23]. In contrast, in a study comprising 136 patients
with heart failure, Narumi and colleagues observed an association
between lower omentin-1 levels and higher risk of cardiac death or
re-hospitalization [21].
Results from cross-sectional studies suggested omentin-1 as a
potential cardio-protective factor, inversely related to cardiovas-
cular risk factors and intermediates. Interestingly, cross-sectional
analyses from our study are in line with previous studies
providing additional evidence regarding cross-sectional associa-
tions between omentin-1 and lifestyle factors, blood lipids and
adiponectin. Our study supports recently reported inverse associ-
ation between omentin-1 and waist circumference [2,3,5]. More-
over, we observed a positive association between omentin-1 and
HDL-cholesterol [3,5,10,24,25] as well as a positive association be-
tween omentin-1 and adiponectin consistent with previous studies
[3,24,26]. In line, also relations between omentin-1 and clinical
intermediate cardiovascular phenotypes were observed. Cross-
sectional studies including patients with type 2 diabetes or MetS,
observed inverse associations between omentin-1 and arterial
stiffness/carotid plaque as well as left ventricular diastolic function
[5,27]. Moreover, Lui et al. reported an inverse relation between
omentin-1 levels and carotid artery intima-media thickness in
MetS patients [4]. Nevertheless, these ﬁndings were observed in
studies comprising low number of participants with existing dis-
eases. Interestingly, restricting our results to a subgroup of.
p for interactionb Hazard ratio (95%-CI)c p-value
0.68
2.65 (1.55e4.52) 0.0004
1.90 (1.06e3.40) 0.03
0.03
2.59 (1.63e4.11) <0.0001
1.76 (0.82e3.77) 0.15
0.05
2.58 (1.64e4.07) <0.0001
1.21 (0.59e2.50) 0.60
0.49
2.76 (1.23e6.17) 0.01
2.16 (1.38e3.38) 0.0007
0.09
3.16 (1.90e5.25) <0.0001
1.28 (0.73e2.26) 0.39
0.02
1.14 (0.65e2.01) 0.65
3.52 (2.08e5.94) <0.0001
0.08
2.98 (1.70e5.21) 0.0001
1.49 (0.83e2.66) 0.18
ormed omentin-1 levels.
alcohol consumption, prevalent hypertension and diabetes, HDL-cholesterol, total
J. Menzel et al. / Atherosclerosis 251 (2016) 415e421420participants with MetS we also observed an inverse, though non-
signiﬁcant, association between omentin-1 and risk of MI. There-
fore we may hypothesize that the role of omentin-1 in metabolic
regulation probably systematically differs in participants with pre-
existing metabolic disease as compared to those apparently
healthy. However, the suggested protective effect was not observed
in stratiﬁed analysis regarding risk of stroke, although a lower risk
in participants with MetS was observed, compared to participants
without MetS.
With regard to stroke risk, we observed a signiﬁcant positive
interaction between omentin-1 and waist circumference as well as
between omentin-1 and adiponectin. Interestingly, adiponectin
and omentin-1 share the same pattern of physiological effects i.e.
both are downregulated in obesity [3,28], both have been proposed
to have a beneﬁcial effect on glucose metabolism and insulin
sensitivity [1,29], and both were discussed as cardio-protective
adipokines [28,30]. However, the association between omentin-1
and stroke risk was particularly strong among individuals with
high adiponectin levels compared to those with low levels. There-
fore, a complex molecular interplay between omentin-1 and adi-
ponectin in relation to risk of strokemight be hypothesized. Yet, the
available evidence is insufﬁcient to infer a possible mechanism
explaining the observed interaction between omentin-1 and adi-
ponectin. To date, it is uncertain whether the regulation of
omentin-1 may be dependent on adiponectin or vice versa [3]. So
far, only Herder et al. have hypothesized that circulating omentin-1
levels regulate adiponectin levels [24].
Up to date, experimental studies have suggested omentin-1 as a
potential cardio-protective factor [31e37]. Yamawaki et al. have
shown that omentin-1 may enhance vasodilation in vascular
endothelial cells vessels through endothelium-derived nitric oxide
[31]. In addition, omentin-1 has been suggested to increase AMP-
activated protein kinase (AMPK) phosphorylation, and to promote
endothelial cell function e.g. enhancement of endothelial cell dif-
ferentiation [32], protection of cardiac myocytes from apoptosis
during ischemia [33] and attenuate neointimal formation after
arterial injury in vivo [34]. Furthermore, omentin-1 may exert anti-
inﬂammatory functions via AMPK signaling pathway [35e37].
However, as already mentioned in line with our study results,
recently another prospective study by Sealy et al. refuted the sug-
gested cardio-protective associations and in addition demonstrates
that omentin-1 strongly predicts cardiovascular events [22,23]. Yet,
the reasons for such discrepant ﬁndings are unclear, demonstrating
that the biological action of omentin-1 in the cardiovascular
biology is hardly understood. So far, we might speculate, somehow,
an omentin-1-related stroke risk depended from different meta-
bolic conditions e.g. high or low level of adiponectin, triglycerides
or hsCRP. Competition for possible shared signal pathways with
different signaling efﬁciencies would in principle agree with our
observations.We suspect amolecular interplay between omentin-1
and other CVD risk factors to be of complex nature and to be
probably altered in the pathophysiological context.
However, given the strong associations between higher
omentin-1 levels and stroke risk on the one hand and the non-
signiﬁcant relation with MI on the other hand, intense research
and well-designed experiments are needed, addressing the bio-
logical processes of omentin-1 with the risk of different major
cardiovascular endpoints under different metabolic conditions.
Strengths of the current study include the prospective study
design, the availability of high quality data as a result of the stan-
dardized procedures enabling us to adjust for a large variety of
potential confounders, the high follow-up response rate, and the
rigorous case validation. Nevertheless, the present results are
limited to middle aged Caucasian participants and might be not
generalized to other ethnic groups. The competing risk analysesrevealed no signiﬁcant differences in the association omentin-1
and ischemic stroke compared to hemorrhagic stroke, but based
on the limited number of cases, in particular for hemorrhagic
stroke, a chance ﬁnding cannot be completely ruled out. Further-
more, the present ﬁndings are based on one single baseline mea-
surement of omentin-1 levels with long-term sample storage.
Nevertheless, EPIC-Potsdam provides high quality blood samples,
because of the highly standardized processes for sample collection
and storing. Plasma samples used for omentin-1 assessment were
stored at 80 C in freezers, a temperature that guarantees the
stability of samples for long periods of time for a wide range of
analytes, including highly labile molecules such as cytokines
[38,39]. Moreover, we observed excellent reliability of omentin-1
over time indicated by intraclass correlation coefﬁcient (ICC) of
0.83 (95%-CI 0.78e0.87), which was very similar to the ICC reported
from a previous study [40], suggesting that a single measurement
may provide reliable risk estimates [41].
In conclusion, the current study observed that high plasma
omentin-1 concentrations were associated with a higher risk of
stroke in particular in participants with normal waist circumfer-
ence, low levels of triglyceride and hsCRP, high adiponectin levels
or no metabolic syndrome. Further studies are needed to explain
the different role of omentin-1 under different metabolic
conditions.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding conﬂict of interest with respect to this manuscript.
Financial support
This project was conducted within the framework of the topic
ﬁeld “Metabolische Dysfunktion und Volkserkrankungen, Teilpro-
jekt: Metabolische Dysfunktion, Entzündungen und
kardiovaskul€are Krankheiten sowie metabolische Dysfunktionen
und Tumorerkrankungen”, supported by the Helmholtz Associa-
tion. Furthermore the study was supported by a grant from the
German Federal Ministry of Education and Research (BMBF) to the
German Center for Diabetes Research (DZD).
Acknowledgements
We thank the Human Study Centre (HSC) of the German Insti-
tute of Human Nutrition Potsdam-Rehbrücke, namely the trustee
and the examination unit for the collection, the data hub for the
processing, and the participants for the provision of the data, the
biobank for the processing of the biological samples and the head of
the HSC, Manuela Bergmann, for the contribution to the study
design and leading the underlying processes of data generation.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2016.06.003.
References
[1] R.Z. Yang, M.J. Lee, H. Hu, et al., Identiﬁcation of omentin as a novel depot-
speciﬁc adipokine in human adipose tissue: possible role in modulating in-
sulin action, Am. J. Physiol. Endocrinol. Metab. 290 (2006) E1253eE1261.
[2] B.K. Tan, R. Adya, H.S. Randeva, Omentin: a novel link between inﬂammation,
diabesity, and cardiovascular disease, Trends Cardiovasc. Med. 20 (2010)
143e148.
[3] C.M. de Souza Batista, R.Z. Yang, M.J. Lee, et al., Omentin plasma levels and
gene expression are decreased in obesity, Diabetes 56 (2007) 1655e1661.
[4] R. Liu, X. Wang, P. Bu, Omentin-1 is associated with carotid atherosclerosis in
J. Menzel et al. / Atherosclerosis 251 (2016) 415e421 421patients with metabolic syndrome, Diabetes Res. Clin. Pract. 93 (2011) 21e25.
[5] S. Greulich, W.J. Chen, B. Maxhera, et al., Cardioprotective properties of
omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies, PLoS
One 8 (2013) e59697.
[6] X. Zhong, H.Y. Zhang, H. Tan, et al., Association of serum omentin-1 levels with
coronary artery disease, Acta Pharmacol. Sin. 32 (2011) 873e878.
[7] F.J. Shang, J.P. Wang, X.T. Liu, et al., Serum omentin-1 levels are inversely
associated with the presence and severity of coronary artery disease in pa-
tients with metabolic syndrome, Biomarkers 16 (2011) 657e662.
[8] I. Onur, F. Oz, S. Yildiz, et al., Serum omentin 1 level is associated with coro-
nary artery disease and its severity in postmenopausal women, Angiology 65
(2014) 896e900.
[9] R. Shibata, N. Ouchi, R. Kikuchi, et al., Circulating omentin is associated with
coronary artery disease in men, Atherosclerosis 219 (2011) 811e814.
[10] X.H. Wang, L.Z. Dou, C. Gu, et al., Plasma levels of omentin-1 and visfatin in
senile patients with coronary heart disease and heart failure, Asian Pac. J.
Trop. Med. 7 (2014) 55e62.
[11] H. Boeing, J. Wahrendorf, N. Becker, EPIC-GermanyeA source for studies into
diet and risk of chronic diseases, Eur. Investig. Cancer Nutr. Ann. Nutr. Metab.
43 (1999) 195e204.
[12] C. Weikert, N. Stefan, M.B. Schulze, et al., Plasma fetuin-a levels and the risk of
myocardial infarction and ischemic stroke, Circulation 118 (2008)
2555e2562.
[13] C. Weikert, K. Berger, C. Heidemann, et al., Joint effects of risk factors for
stroke and transient ischemic attack in a German population: the EPIC Pots-
dam study, J. Neurol. 254 (2007) 315e321.
[14] C. Weikert, D. Drogan, R. di Giuseppe, et al., Liver enzymes and stroke risk in
middle-aged German adults, Atherosclerosis 228 (2013) 508e514.
[15] H. Tunstall-Pedoe, K. Kuulasmaa, P. Amouyel, et al., Myocardial infarction and
coronary deaths in the World Health Organization MONICA Project. Regis-
tration procedures, event rates, and case-fatality rates in 38 populations from
21 countries in four continents, Circulation 90 (1994) 583e612.
[16] World Health Organization, International Statistical Classiﬁcation of Diseases
and Related Health Problems, World Health Organization, Geneva,
Switzerland, 1992.
[17] R.L. Prentice, A case-cohort design for epidemiologic cohort studies and dis-
ease prevention trials, Biometrika 73 (1986) 1e11.
[18] M. Lunn, D. McNeil, Applying Cox regression to competing risks, Biometrics 51
(1995) 524e532.
[19] S.M. Grundy, H.B. Brewer Jr., J.I. Cleeman, et al., Deﬁnition of metabolic syn-
drome: report of the National Heart, Lung, and Blood Institute/American Heart
Association conference on scientiﬁc issues related to deﬁnition, Circulation
109 (2004) 433e438.
[20] F.T. Fischbach, M.B. Dunning III, Manual of laboratory and diagnostic tests,
Lippincott Williams Wilkins 8 (2009) 642e643.
[21] T. Narumi, T. Watanabe, S. Kadowaki, et al., Impact of serum omentin-1 levels
on cardiac prognosis in patients with heart failure, Cardiovasc Diabetol. 13
(2014) 84.
[22] C.H. Saely, A. Leiherer, A. Muendlein, et al., High plasma omentin predicts
cardiovascular events independently from the presence and extent of an-
giographically determined atherosclerosis, Atherosclerosis (2015), http://
dx.doi.org/10.1016/j.atherosclerosis.2015.10.100.
[23] C.H. Saely, A. Leiherer, A. Muendlein, et al., Coronary patients with high
plasma omentin are at a higher cardiovascular risk, Data Brief 6 (2016)
158e161.
[24] C. Herder, D.M. Ouwens, M. Carstensen, et al., Adiponectin may mediate theassociation between omentin, circulating lipids and insulin sensitivity: results
from the KORA F4 study, Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 172 (2015)
423e432.
[25] I. Jialal, S. Devaraj, H. Kaur, et al., Increased chemerin and decreased omentin-
1 in both adipose tissue and plasma in nascent metabolic syndrome, J. Clin.
Endocrinol. Metab. 98 (2013) E514eE517.
[26] P. Yan, D. Liu, M. Long, et al., Changes of serum omentin levels and relation-
ship between omentin and adiponectin concentrations in type 2 diabetes
mellitus, Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Dia-
betes Assoc. 119 (2011) 257e263.
[27] H.J. Yoo, S.Y. Hwang, H.C. Hong, et al., Association of circulating omentin-1
level with arterial stiffness and carotid plaque in type 2 diabetes, Car-
diovasc Diabetol. 10 (2011) 103.
[28] C. Caselli, A. D’Amico, M. Cabiati, et al., Back to the heart: the protective role of
adiponectin, Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 82 (2014) 9e20.
[29] S.E. Park, C.Y. Park, G. Sweeney, Biomarkers of insulin sensitivity and insulin
resistance: past, present and future, Crit. Rev. Clin. Lab. Sci. (2015) 1e11.
[30] W. Zhu, K.K. Cheng, P.M. Vanhoutte, et al., Vascular effects of adiponectin:
molecular mechanisms and potential therapeutic intervention, Clin. Sci. 114
(2008) 361e374.
[31] H. Yamawaki, N. Tsubaki, M. Mukohda, et al., Omentin, a novel adipokine,
induces vasodilation in rat isolated blood vessels, Biochem. Biophys. Res.
Commun. 393 (2010) 668e672.
[32] S. Maruyama, R. Shibata, R. Kikuchi, et al., Fat-derived factor omentin stim-
ulates endothelial cell function and ischemia-induced revascularization via
endothelial nitric oxide synthase-dependent mechanism, J. Biol. Chem. 287
(2012) 408e417.
[33] Y. Kataoka, R. Shibata, K. Ohashi, et al., Omentin prevents myocardial ischemic
injury through AMP-activated protein kinase- and Akt-dependent mecha-
nisms, J. Am. Coll. Cardiol. 63 (2014) 2722e2733.
[34] Y. Uemura, R. Shibata, N. Kanemura, et al., Adipose-derived protein omentin
prevents neointimal formation after arterial injury, FASEB J. Off. Publ. Fed. Am.
Soc. Exp. Biol. 29 (2015) 141e151.
[35] K. Kazama, T. Usui, M. Okada, et al., Omentin plays an anti-inﬂammatory role
through inhibition of TNF-alpha-induced superoxide production in vascular
smooth muscle cells, Eur. J. Pharmacol. 686 (2012) 116e123.
[36] H. Yamawaki, J. Kuramoto, S. Kameshima, et al., Omentin, a novel adipocy-
tokine inhibits TNF-induced vascular inﬂammation in human endothelial
cells, Biochem. Biophys. Res. Commun. 408 (2011) 339e343.
[37] K. Ohashi, R. Shibata, T. Murohara, et al., Role of anti-inﬂammatory adipokines
in obesity-related diseases, Trends Endocrinol. Metab. TEM 25 (2014)
348e355.
[38] P. Elliott, T.C. Peakman, U.K. Biobank, The UK Biobank sample handling and
storage protocol for the collection, processing and archiving of human blood
and urine, Int. J. Epidemiol. 37 (2008) 234e244.
[39] M.R. Lewis, P.W. Callas, N.S. Jenny, et al., Longitudinal stability of coagulation,
ﬁbrinolysis, and inﬂammation factors in stored plasma samples, Thromb.
Haemost. 86 (2001) 1495e1500.
[40] G. Panagiotou, L. Mu, B. Na, et al., Circulating irisin, omentin-1, and lipoprotein
subparticles in adults at higher cardiovascular risk, Metabolism 63 (2014)
1265e1271.
[41] C. Wittenbecher, R. di Giuseppe, R. Biemann, et al., Reproducibility of retinol
binding protein 4 and omentin-1 measurements over a four months period: a
reliability study in a cohort of 207 apparently healthy participants, PLoS One
10 (2015) e0138480.
